Description
With the high therapeutic potential, Immunotherapy in Cancer is expected to become the main agenda of cancer treatment. The recent advances and research studies on Cancer have revolutionized cancer therapy by specifically targeting and destroying certain cancerous cells through the body’s own immune system.
The upcoming webinar with Dr. Shibichakravarthy Kannan will help you understand the great advancements in Cell based Cancer therapy
Summary Listen
- The presentation focuses on diagnostics for immunotherapies, particularly cell-based therapies like CAR-T cells. It emphasizes the importance of understanding the tumor microenvironment, classifying tumors as "hot" (T-cell infiltrated) or "cold" (lacking immune recognition). Hot tumors tend to respond better to immunotherapy, while cold tumors pose a greater challenge.
- Liquid biopsy, specifically circulating tumor DNA (ctDNA) sequencing using nanopore technology, is highlighted as a sensitive tool for monitoring minimal residual disease (MRD) and identifying patients suitable for immunotherapy. This approach goes beyond traditional genotyping, incorporating epigenetic changes and fragment distributions for a more comprehensive analysis.
- CAR-T cell therapy involves genetically engineering T-cells to target cancer-specific antigens. Different generations of CAR-T cells have evolved, with later generations incorporating co-stimulatory molecules and on/off switches for improved efficacy and safety. The presentation lists several FDA-approved CAR-T cell therapies, including those targeting CD19 for B-cell lymphomas and BCMA for multiple myeloma.
- The manufacturing process of CAR-T cells involves isolating and activating T-cells, transducing them with viral vectors to introduce the CAR construct, expanding the cells, and performing quality control. Companies like Miltenyi Biotec provide closed, automated systems for GMP-compliant CAR-T cell production.
- Neoantigens, unique mutations in cancer cells that can be recognized by the immune system, are discussed as potential targets for personalized immunotherapy. mRNA-based therapies are explored as a means of inducing immune responses against neoantigens. However, the development of neoantigen-based therapies is complex and expensive, requiring HLA typing and single-cell genomics.
- Potential adverse events associated with CAR-T cell therapy, such as cytokine release syndrome (CRS) and neurotoxicity, are discussed. These complications can be managed with supportive care and medications like tocilizumab. Clinical trials of CAR-T cells are ongoing, but companies often face regulatory hurdles.
Sample Certificate
About the Speakers
Dr. Shibichakravarthy Kannan
Precision Oncology, Founder & CEO in Oncophenomics Inc., Hyderabad
Comments
Comments
You must be logged in to leave a comment.